2. I.R.C.C.S. Policlinico San Matteo, Pavia
Platinum series:
best papers on RCC in 2013
Dr. Camillo Porta
S.C. di Oncologia Medica
I.R.C.C.S. Policlinico San Matteo, Pavia

3. What I wanted to tell you about …
but I can’t
The final publication of the COMPARZ trial (already accepted by the NEJM)
The final publication of the PISCES trial (revision just submitted to the JCO)

4. Content of the presentation
Therapeutics
final results of the AXIS trial
TKI-mTORI-TKI or TKI-TKI-mTORI?
selection criteria for immunotherapy and its efficacy post-TKIs
Prognostic criteria
validation of the Heng’s score
prognostic factors for survival in Sunitinib-treated patients
Translational research
Sunitinib Tx and tumor growth

5. The AXIS trial

6. AXIS trial final OS results

7. AXIS trial final OS results: overall patient population

8. AXIS trial final OS results:
other analyses
Post Sunitinib
Post cytokines

9. Patient Reported Outcomes
AXIS trial results:
Patient Reported Outcomes

10. AXIS trial results:
no differences in PROs

11. Which sequence over
3 lines of treatment?

12. Few patients receive 3 drugs, but
the winner is …

13. high-dose IL-2 immunotherapy
Targeted agents after
high-dose IL-2 immunotherapy

14. High-dose IL-2 immunotherapy:
which patients?

15. High-dose IL-2 immunotherapy
after targeted agents
Does these results
really mean something?

16. Validation of the
Heng’s criteria

17. Different models compared

18. And the winner is …

19. Prognostic factors for survival in
Sunitinib treated pts

20. Prognostic factors for Sunitinib:
nihil novo sub solem
Motzer RJ et al. BJC 2013

21. Sunitinib and tumor growth

22. Is a strong angiogenesis inhibition
linked to a rapid tumor progression?

23. Sunitinib does not alter
tumor biology in vivo

24. Thank You for Your kind attention!!!